1. Diabetes Treatment: How Novo Nordisk Is Taking On Other Pharmaceutical Companies  Investor's Business Daily
  2. ADA: Novo Nordisk's oral semaglutide posts another heart safety win  FiercePharma
  3. View full coverage on Google News

Access to this page has been denied.

Novo Nordisk may have already submitted its approval application for its oral GLP-1 drug semaglutide, but the deluge of positive data hasn’t stopped.Novo Nordisk may have already submitted its approval application for its oral GLP-1 drug semaglutide, but the deluge of positive data hasn’t stopped.

ADA: Novo Nordisk's oral semaglutide posts another heart safety win | FiercePharma